OS0250H

The OVIVA Trial: Oral versus intravenous antibiotics in the management of bone and joint infection - a multicentre open label randomised non-inferiority study.

Matthew Scarborough*1, LI Ho Kwong2, Ines Rombach3, Rhea Zambellas3, Benjamin A. Lipsky4, Harriet Hughes5, Deepa Bose6, Simon Warren7, Jonathan Folb8, Elinor Moore9, Neil Jenkins10, Susan Hopkins11, Andrew Seaton12, Carolyn Hemsley13, Jonathan Sandoe14, Nicola Mcmeekin15, Martin Mcnally1, Sarah Walker16, Guy Thwaites17, Philip Bejon18

1Nuffield Orthopaedic Centre; Bone Infection Unit; Oxford University Hospitals
2Imperial College; Division of Infectious Diseases
3Ndorms; Oxford University
4University of Oxford; Medicine; Infectious Diseases
5Public Health Wales / University Hospital of Wales; Microbiology Department
6University Hospitals Birmingham
7Royal Free Hospital, London, Uk; Royal National Orthopaedic Hospital, Stanmore
8Royal Liverpool and Broadgreen University Hospitals
9Addenbrookes Hospital
10Birmingham Heartlands Hospital
11Royal Free Hospital
12Queen Elizabeth University Hospital
13Guys and St Thomas NHS Foundation Trust
14Leeds Teaching Hospitals and University of Leeds; Microbiology, Old Medical School
Background: Management of bone and joint infection commonly includes a prolonged course of intravenous antibiotics, but without clear evidence of an advantage over oral therapy. We set out to establish whether clinical outcomes are non-inferior in patients managed primarily with oral antibiotics as compared to intravenous antibiotics (ISRCTN91566927).

Material/methods: Adults presenting with bone, joint or orthopaedic metalware-associated infection, who had received ≤7 days of intravenous antibiotics following definitive surgery (or the start of planned curative therapy if managed conservatively), were randomised to either oral or IV antibiotics to complete the initial 6 weeks of therapy. The choice of agent was determined by an infection specialist. Adjunctive oral rifampicin and follow-on therapy beyond six weeks were permitted in either arm. The primary endpoint was definitive treatment failure within one year of randomisation, as assessed by a blinded endpoint committee. Secondary endpoints included SAEs, line complications, C. difficile diarrhoea, resource allocation and quality of life (EQ-5D). Emerging data are presented here; final results by randomisation arm will be available for presentation at ECCMID.

Results: Between June 2010-October 2015, 1054 participants, including 228 from a pilot study, were randomized across 26 UK sites; median age (IQR) was 60 (49,70) and 64% were male. The most common baseline surgical procedures were debridement of osteomyelitis in 322 (31%) participants, removal of orthopaedic device/joint implant in 302 (29%), DAIR in 247 (23%) and single-stage revision in 90 (9%). The lower limb was involved in 855 (81%) cases (hip 214, knee 248, foot 175, other 218), the upper limb in 102 (10%) and the spine in 72 (7%). Common co-morbidities included diabetes (19%) and smoking (13%). Histological confirmation of infection was available in 543 (52%) cases; in 409 (39%), no samples were submitted for histology. Microbiologically, 157 (15%) cases were culture-negative, and in 41 (4%) no samples were submitted for culture. S. aureus, coagulase-negative staphylococci and streptococci were identified in 381/1004 (38%), 273/1004 (27%) and 146/1004 (15%) respectively, and Gram-negative organisms in 220/1004 (22%). For those randomised to IV therapy, glycopeptides and cephalosporins were used in 214/521 (41%) and 173/521 (33%) respectively; for oral therapy, quinolones and penicillins were used in 191/523 (37%) and 83/523 (16%) respectively. The median (IQR) duration of hospitalisation was 13 (9,22) days, and 785/1049 (74%) patients continued antibiotic therapy beyond 6 weeks. 444 serious adverse events were reported in 284/1054 (27%) patients; 103/444 (23%) were graded as severe. Thirty-nine participants were withdrawn or lost to follow-up without having met a primary endpoint; complete case analysis will therefore include 1015 patients (96%).

Conclusions: If oral therapy proves non-inferior to IV therapy in bone and joint infection, potential gains are possible for length of hospital stay, complication rate, antimicrobial stewardship, patient convenience and treatment costs.